Hemorrhage induced by intrauterine devices: control by local proteinase inhibition.
The intrauterine application of proteinase inhibitors, tranexaminc acid and the pancreatic trypsin inhibitor (Trasylol), reduces or eliminates menorrhagia and intermenstrual bleeding (spotting) produced by an intrauterine device (IUD). A decrease in pain and vaginal (cervical) discharge is also frequently observed. A single application is usually sufficient, more than three never being required. The effect lasts for an average of three cycles. In addition to the clinical use of these agents for the treatment of uterine hemorrhage, the slow release of proteinase inhibitors from an IUD may well be useful in minimizing its side effects without interfering with its contraceptive activity.
D000287:Administration, Topical; D003509:Cyclohexanecarboxylic Acids / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D007435:Intrauterine Devices, Copper / Q000009:adverse effects*; D008595:Menorrhagia / Q000188:drug therapy* / Q000209:etiology; D010455:Peptides / Q000008:administration & dosage; D014148:Tranexamic Acid / Q000008:administration & dosage* / Q000627:therapeutic use; D014361:Trypsin Inhibitors / Q000008:administration & dosage* / Q000627:therapeutic use
D003509:Cyclohexanecarboxylic Acids; D010455:Peptides; D014361:Trypsin Inhibitors; D014148:Tranexamic Acid